Medical Innovation at Sheba Medical Center

20-08-2014

Web-search key: Sheba Medical Center, Technology transfer,  Innovation, Medical Device, Diagnosis, Seldinger,  Heart catheter, PAR-1, Glaucoma, Citrullinated peptide, Rheumatoid Arthritis, cCAM, Melanoma, Kidney failure, Stem cells, Hutchison, Biofilm, ACCUTOME, Field of vision, Dr. Leonid Sternik, Dr. Avinoam Nevler, Prof. Yoav Chapman, Dr. Illia Piven, Prof. Haward Amital.   

 

Tel Hashomer Medical Research, Infrastructure and Services Ltd.  (THM) has been established as a "company for the benefit of the public" to promote the transfer of technologies, innovation and professional know-how generated by the hospital employees, for society's use and benefit, and for the development of the medical and health care delivery fields.   Currently, The Sheba Medical Center (SMC) is the leading hospital in Israel in medical research, including Patent Applications and Licensing Agreements. Our IP portfolio spans vast medical fields including therapeutics, diagnostic tools, imaging modalities, drug delivary systems, medical devices and more.

 

The Sheba Medical Center provides comprehensive R&D services in a unified environment from the initial stages and up to the clinical trials. Our cutting-edge technologies, supported by world-renowned researchers, make us an ideal choice for your company.  

 

 

Making a Difference in Treating Human Diseases

 

THM took a pro-active part in the Israeli annual BIOMED- MIXiii conference, that  took place at the Tel Aviv Fairgrounds May 20-22, 2014, meeting both local and foreign companies and investors, presenting medical innovations and technologies in order to promote collaboration and technology transfer.

 

 

The logos of the participants Technology Transfer Offices

Tel-Aviv fairground hosting the annual BIOMED-MIXiii

                

The new format of the conference   encompasses   both the biomed and high-tech members of the Israel Advanced Technology Industries (IATI) - the Israeli organization representing high-tech, biomed and multinational corporations, startups, incubators, accelerators, academic technology transfer offices, venture capital funds, service providers and more.

 

 

Left to right: Prop. Arie Orenstein with Mr. Louis P. Berneman

Left to right: Prop. Shlomo Noy, Mrs. Tal Noy, Mr. Uzia Galil and Prof. Michael Belkin

 

 

 

Examples for early stage technologies at The Sheba Medical Center:

A port access device to treat atrial fibrillation. Left atrial appendage (LAA) is a place of blood clot formation and source of emboli in patients with atrial fibrillation. A complicated procedure for occlusion of the left atrial suits patients that can't be treated with Warfarin (Coumadin) but still a very high risk solution for many others. Completed with a unique method invented by Dr. Leonid Sternik from the Cardiac Surgery
Department, the treatment with a designated catheter to left atrial occlusion can provide a low risk and simple solution.

 

A novel Veress insufflation needle having an expandable element allowing a Seldinger like insertion of a pre-placed trocar and limiting its insertion depth with the mentioned expandable element. The development of few surgeons led by Dr. Avinoam Nevler.

 

Development of novel protease activating receptor 1 (PAR-1) based therapeutic compounds for neuroinflammatory and malignant diseases like diabetic neuropathy, glioma, melanoma and more. Prof. Yoav Chapman's laboratory designed new compositions, based on the thrombin binding sequence of PAR-1,   targeting the increased protease activity found in disease states and specifically protects PAR-1.

 

The invention of Dr. Illia Piven, Ophthalmologist at the Sheba Medical Center, demonstrates an implantable medical device for ocular drainage for treating Glaucoma patients. The device will be implanted in the eye as treatment or after a failure of surgery or laser procedure.

 

Citrullinated peptides for diagnosis and treatment of Rheumatoid Arthritis (RA) as an innovative approach for minimal-treatment. This novel composition wase discovered by Prof. Haward Amital, a Rheumatologist at the Sheba Medical Center, to deal with the crucial need in RA to restore the breakdown tolerance via induction of tolerance using citrullinated peptides that will assist to ameliorates arthritis manifestations.

 

This short list provides a taste of the multidisciplinary research activities, emphasizing the applicative approach of The Sheba Medical Center's inventions.  As of today, THM owns 105 patent families. Moreover, The Sheba Medical Center's patent committee examines dozens of new applications every year and approves between 15-17 of the potentially best industrial inventions.

 

To date, more than 55% of THM's inventions were transferred to industry. For example:

 

cCam Biotheraputics is a company that develops unique antibodies for the treatment of melanoma.  Based on the invention of Prof. Jacob Shechter and Dr. Gal Merckel from the Ella Institute at the Sheba Medical Center.

 

KidneyCure is a company that develops methods and products based on kidney stem cells to treat renal failure. Based on the inventions of Prof. Benny Dekel and Dr. Orit Steinberg from the Pediatric Stem Cell Research Institute at the Sheba Medical Center.

 

Hutchison Biofilm Medical Solution Limited develops special material that prevents bacterial growth and culture. Based on the invention of Dr. Amir Zlotkin at the Sheba Medical Center.

 

ACCUTOME is a company that develops a device for automatic measurement of the field of vision. A device that will help diagnosis of ophthalmology pathologies,  CNS, neuro degenerative diseases and trauma. Based on the invention of Dr. Ygal Rotenstreich at the Sheba Medical Center.

 

THM is proactive with SMC's medical team to facilitate the development of any invention through the entire process in an effort to maximize revenue potential. SMC enriches its staff with an optimal working research environment to support their clinical as well as R&D products.

 

In the last decade, THM built a strong network of collaborations with the global industry and venture capitals and with federal funds in Israel. The great variety of Intellectual Property (IP) portfolio and business activities in the local and the foreign biomedical industries has located THM on the global map. THM is committed to bring innovation from the medical team to the patient for the general use of the medical community.

 

For more information on The Sheba Medical Center's inventions please follow the links at the R&D site.